Levothyroxine Treatment in Thyroid Benign Nodular Goiter
|ClinicalTrials.gov Identifier: NCT00552253|
Recruitment Status : Completed
First Posted : November 1, 2007
Last Update Posted : December 22, 2010
|Condition or disease||Intervention/treatment|
|Thyroid Nodule||Drug: Levothyroxin treatment|
OBJECTIVE - Current treatment of benign thyroid is oral levothyroxin by suppression of thyrotropin secretion and so that tumor growth. Although current consensus is taking thyroxin one hour before meal because the PH value of gastrointestinal tract will affect drug absorption, some patient suffered from epigastric discomfort when taking thyroxin with empty stomach, and wish to take it postprandial. However, there is no direct evidence showing if taking thyroxin at different time point significantly affects treatment outcome. Besides, the response to thyroxin therapy differs among people. The purposes of this study are to evaluate the clinical significance of different time points of thyroxine intake and to search factors relating to thyroxin response of benign thyroid tumors.
RESEARCH DESIGN AND METHODS - We will include patients who have benign thyroid tumors diagnosed with fine needle aspiration cytology and have normal thyroid function into our study. After informed consent, patients will be randomly assigned into two groups. Patients in the first group will take thyroxin one hour before breakfast until thyrotropin level stabilized between 0.5 and 1.0 mU/L for 3 months. Then thyroxin will be discontinued. Patients will restart thyroxin therapy three months later but after breakfast. Patients in another group will take thyroxin postprandial, discontinue thyroxin and then one hour before breakfast. Questionnaire interviews about diet and life style, blood samples and fine needle aspiration cytology samples will be obtained. Changes of thyroid nodules will be evaluated with thyroid echo.
STATISTIC ANALYSIS - Descriptive data will be described as means and SDs for continuous variables, and analysis of variance and Chi-square tests were used for assessing the significances. A p-value below 0.05 was considered significant.
Keywords: benign thyroid tumor, thyroxin, preprandial, postprandial.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Official Title:||Levothyroxine Treatment in Thyroid Benign Nodular Goiter|
|Study Start Date :||October 2007|
|Primary Completion Date :||July 2008|
|Study Completion Date :||July 2008|
Drug: Levothyroxin treatment
Levothyroxin 100 micogram will be administered once daily 1 hour before meal of just after meal for 3 months, and the dose will be titrate to keep serum TSH level between 0.1~0.3 mU/L. It will be discontinued for 3 months. Then
- The size of thyroid nodules [ Time Frame: 3 months after levothyroxine treatment ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00552253
|National Taiwan University Hospital|
|Dou-Liou city, Yun-Lin County, Taiwan|
|Principal Investigator:||Shyang-Rong Shi, M.D.||National Taiwan University Hospital, Yun-Lin Branch|